Biovian Makes $55 Million Investment in Finland Manufacturing Facility

The expansion project is expected to be completed in December 2024, with the new facility fully operational by 2025.

Biovian Oy, a contract development and manufacturing organization (CDMO) that specializes in biopharmaceuticals, has made an investment of over $55 million to expand its manufacturing facility in Turku, Finland.

The new facility will cover an area of 69,000 square feet, and house equipment and advanced technologies that support the development, manufacturing, and testing of ATMPs (advanced therapy medicinal products), including adenoviral and AAV (adeno-associated viral) therapies. It will also feature dedicated Class A to D cleanroom areas for bulk drug substances, along with final drug product manufacture. The expanded facility will follow current good manufacturing practices (cGMP) and fulfilling both EU and US GMP requirements, ensuring the delivery of safe, reliable, and compliant biopharmaceutical products.

The goal of the move is to meet the growing demand for high-quality biopharma manufacturing services—together with Biovian’s existing manufacturing facility, the new premises will increase the total area up to 123,800 square feet. The additional space complements Biovian’s existing manufacturing facilities in the area and will enable Biovian to undertake larger-scale viral vector as well as microbial protein projects and concurrent manufacturing campaigns by increasing overall production capacity and flexibility.

The expansion project is expected to be completed in December 2024, with the new facility fully operational by 2025.

“The new manufacturing facility will not only strengthen Biovian’s position as a key player in the CDMO sector, but also contribute to the growth of the biopharmaceutical industry in Finland and most of all, provide vital therapies to patients suffering from today’s untreatable diseases,” says Antti Nieminen, CEO of Biovian.